Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of Apatinib plus Camrelizumab combined with docetaxel and S-1 as the first-line treatment of metastatic adenocarcinoma of gastric and gastroesophageal junction.
Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma
DRUG: Camrelizumab|DRUG: Apatinib Mesylate|DRUG: S1|DRUG: Docetaxel injection
Progression-Free Survival (PFS), PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator, 36 months
objective response rate (ORR), Defined as percentage of participants achievingassessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1., 36 months|overall survival (OS), OS is the time from enrollment to death due to any cause., 36 months|disease control rate (DCR), DCR was defined as the percentage of participants who have a confirmed complete response（CR） or partial response（PR） or stable disease（SD） per RECIST 1.1 as assessed by investigator, 36 months|adverse events (AE), overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use., 36 months
The purpose of this study is to evaluate the efficacy and safety of Apatinib plus Camrelizumab combined with docetaxel and S-1 as the first-line treatment of metastatic adenocarcinoma of gastric and gastroesophageal junction.